Trade Mark Journal No.2026/045 6 November 2026

WO0000001931866 (5,42)

Office of origin: United States of America

Date of International Registration:5 June 2026
Date of designation in the UK: 5 June 2026
Image for mark 1931866 EYCONIS

International priority date claimed: 9 December 2025 (United States of America) (99537249)
Class 5
Pharmaceutical preparations for the treatment and alleviation of eye diseases and conditions; pharmaceutical preparations for the treatment and alleviation macular degeneration, diabetic macular edema, retinal vein occlusion, and geographic atrophy; medicines for use in ophthalmology treatments.
Class 42
Medical research; medical research in the fields of ophthalmology, eye disease, and eye conditions; medical research in the field of pharmaceutical preparations for the treatment and alleviation of eye disease and conditions; medical research in the field of pharmaceutical preparations for the treatment and alleviation macular degeneration, diabetic macular edema, retinal vein occlusion, and geographic atrophy; pharmaceutical drug development; pharmaceutical drug development in the fields of ophthalmology and eye disease; pharmaceutical drug development in the field of pharmaceutical preparations for the treatment and alleviation macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and geographic atrophy (GA); research and development of new products for medicinal use for others.

Eyconis, Inc.

Representative: Abion UK Limited, The Forum, St Paul's, 33 Gutter Lane London EC2V 8AS UNITED KINGDOM